首页 > 最新文献

Therapeutics and Clinical Risk Management最新文献

英文 中文
Central Oxygen Venous Saturation and Mortality in Patients Undergoing Coronary Artery Bypass Grafting. 冠状动脉旁路移植术患者的中心静脉氧饱和度和死亡率。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S407454
María A Rodríguez-Scarpetta, Andrés M Sepúlveda-Tobón, Jorge E Daza-Arana, Heiler Lozada-Ramos, Rodrigo A Álzate-Sánchez

Purpose: Central venous oxygen saturation (ScvO2) has been reported as a prognostic marker of in-hospital mortality when it is below 60% in certain situations. Nevertheless, it has not been widely reported in patients undergoing coronary artery bypass graft (CABG). The study determined the association between ScvO2 and in-hospital mortality in patients undergoing CABG in a high-complexity health institution in Santiago de Cali, Colombia.

Patients and methods: A retrospective cohort study was conducted with patients undergoing isolated CABG. The subject sample included 515 subjects aged 18 years or older. Exposure was defined as ScvO2 <60% upon admission to the intensive care unit (ICU) following surgery. The major outcome was mortality rates after 30 days. Furthermore, exposure variables were measured at preoperative, intra-operative, and postoperative time points.

Results: A total of 103 exposed and 412 unexposed subjects were included. The final model revealed a higher mortality risk in individuals with ScvO2 <60% upon ICU admission compared with those with higher saturation levels (relative risk 4.2, 95% confidence interval: 2.4-7.2; p = 0.001). Values were adjusted using variables such as age (>75 years), low socioeconomic stratum, chronic kidney failure before surgery, unstable angina before surgery, ischemia time (>60 min), and intra-operative inotrope use. The primary cause of death was cardiogenic shock (54.7%), followed by sepsis (25.0%) and postoperative bleeding (17.2%).

Conclusion: The study identified an association between ScvO2 <60% and in-hospital mortality in patients undergoing CABG.

目的:中心静脉氧饱和度(ScvO2)已被报道为在某些情况下低于60%的住院死亡率的预后标志。然而,在接受冠状动脉旁路移植术(CABG)的患者中并没有广泛的报道。该研究确定了哥伦比亚圣地亚哥de Cali一家高复杂性医疗机构接受CABG患者的ScvO2与住院死亡率之间的关系。患者和方法:对接受孤立性冠脉搭桥的患者进行回顾性队列研究。受试者样本包括515名年龄在18岁或以上的受试者。结果:共纳入103名暴露者和412名未暴露者。最终模型显示ScvO2患者的死亡风险更高(p = 0.001)。使用年龄(>75岁)、低社会经济阶层、术前慢性肾衰竭、术前不稳定型心绞痛、缺血时间(>60分钟)和术中肌力使用等变量对数值进行调整。主要死亡原因为心源性休克(54.7%),其次为败血症(25.0%)和术后出血(17.2%)。结论:该研究确定了ScvO2与
{"title":"Central Oxygen Venous Saturation and Mortality in Patients Undergoing Coronary Artery Bypass Grafting.","authors":"María A Rodríguez-Scarpetta,&nbsp;Andrés M Sepúlveda-Tobón,&nbsp;Jorge E Daza-Arana,&nbsp;Heiler Lozada-Ramos,&nbsp;Rodrigo A Álzate-Sánchez","doi":"10.2147/TCRM.S407454","DOIUrl":"https://doi.org/10.2147/TCRM.S407454","url":null,"abstract":"<p><strong>Purpose: </strong>Central venous oxygen saturation (ScvO<sub>2</sub>) has been reported as a prognostic marker of in-hospital mortality when it is below 60% in certain situations. Nevertheless, it has not been widely reported in patients undergoing coronary artery bypass graft (CABG). The study determined the association between ScvO<sub>2</sub> and in-hospital mortality in patients undergoing CABG in a high-complexity health institution in Santiago de Cali, Colombia.</p><p><strong>Patients and methods: </strong>A retrospective cohort study was conducted with patients undergoing isolated CABG. The subject sample included 515 subjects aged 18 years or older. Exposure was defined as ScvO<sub>2</sub> <60% upon admission to the intensive care unit (ICU) following surgery. The major outcome was mortality rates after 30 days. Furthermore, exposure variables were measured at preoperative, intra-operative, and postoperative time points.</p><p><strong>Results: </strong>A total of 103 exposed and 412 unexposed subjects were included. The final model revealed a higher mortality risk in individuals with ScvO<sub>2</sub> <60% upon ICU admission compared with those with higher saturation levels (relative risk 4.2, 95% confidence interval: 2.4-7.2; <i>p</i> = 0.001). Values were adjusted using variables such as age (>75 years), low socioeconomic stratum, chronic kidney failure before surgery, unstable angina before surgery, ischemia time (>60 min), and intra-operative inotrope use. The primary cause of death was cardiogenic shock (54.7%), followed by sepsis (25.0%) and postoperative bleeding (17.2%).</p><p><strong>Conclusion: </strong>The study identified an association between ScvO<sub>2</sub> <60% and in-hospital mortality in patients undergoing CABG.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/47/11/tcrm-19-447.PMC10246565.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9609865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy. 恩格列净治疗成人慢性肾脏疾病(CKD):目前的证据和在治疗中的地位
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S398163
Gates B Colbert, Hector M Madariaga, Anna Gaddy, Mohamed E Elrggal, Edgar V Lerma

Chronic kidney disease guidelines and disease modifying therapy have seen a dramatic shift in the last 5 years. The SGLT2 inhibitor class of medications has been catapulted from hyperglycemia management medications, to cardiovascular and kidney disease improvement therapies. Multiple trials looking at dedicated cardiovascular and kidney endpoints have resulted in favorable results. This review will target empagliflozin and the exciting journey that it has taken along this path. Empagliflozin has been studied for hyperglycemia, cardiovascular, and kidney hard outcome endpoints. Both patients with diabetes and without have been rigorously studied and shown surprising results. The major implications for patients on empagliflozin will be shown. Future studies and directions are highly anticipated to add to the growing knowledge of the SGLT2 inhibitor class, as well as discover possibilities for new disease states to benefit from empagliflozin.

在过去的5年里,慢性肾脏疾病指南和疾病调节疗法发生了巨大的变化。SGLT2抑制剂类药物已经从高血糖治疗药物迅速发展到心血管和肾脏疾病改善治疗。针对心血管和肾脏终点的多项试验均取得了良好的结果。这篇综述将针对恩格列净和它在这条道路上令人兴奋的旅程。恩格列净已被研究用于高血糖、心血管和肾硬结局终点。糖尿病患者和非糖尿病患者都经过了严格的研究,并显示出令人惊讶的结果。恩格列净对患者的主要影响将被显示。未来的研究和方向备受期待,以增加对SGLT2抑制剂类的不断增长的知识,并发现从恩格列净获益的新疾病状态的可能性。
{"title":"Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy.","authors":"Gates B Colbert,&nbsp;Hector M Madariaga,&nbsp;Anna Gaddy,&nbsp;Mohamed E Elrggal,&nbsp;Edgar V Lerma","doi":"10.2147/TCRM.S398163","DOIUrl":"https://doi.org/10.2147/TCRM.S398163","url":null,"abstract":"<p><p>Chronic kidney disease guidelines and disease modifying therapy have seen a dramatic shift in the last 5 years. The SGLT2 inhibitor class of medications has been catapulted from hyperglycemia management medications, to cardiovascular and kidney disease improvement therapies. Multiple trials looking at dedicated cardiovascular and kidney endpoints have resulted in favorable results. This review will target empagliflozin and the exciting journey that it has taken along this path. Empagliflozin has been studied for hyperglycemia, cardiovascular, and kidney hard outcome endpoints. Both patients with diabetes and without have been rigorously studied and shown surprising results. The major implications for patients on empagliflozin will be shown. Future studies and directions are highly anticipated to add to the growing knowledge of the SGLT2 inhibitor class, as well as discover possibilities for new disease states to benefit from empagliflozin.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/64/tcrm-19-133.PMC9901477.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10689680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Poor Sensorium at the Time of Intubation Predicts Polymicrobial Ventilator Associated Pneumonia. 插管时感觉不良预示着多微生物呼吸机相关性肺炎。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-02-17 eCollection Date: 2022-01-01 DOI: 10.2147/TCRM.S337341
Ramachandran Natarajan, Venkateswaran Ramanathan, Sujatha Sistla

Background: Ventilator-associated pneumonia (VAP) is the most common nosocomial infection in the intensive care unit and is associated with a high mortality rate.

Aim: The study was conducted to estimate the frequency, outcomes, and predictors of polymicrobial VAP.

Methods: A prospective observational study was conducted in mechanically ventilated adult patients in the medical intensive care unit in a tertiary care hospital in India from July 2016 to July 2018 with a 30-day follow-up period. The patients were grouped into monomicrobial and polymicrobial VAP. We compared the 30-day outcome parameters such as discharge from hospital, in-hospital stay, death, and complications such as catheter associated urinary tract infection (CAUTI), central line associated blood stream infection (CRBSI), bacteremia and collapse of lung. The predictors of polymicrobial VAP were identified by multiple logistic regression.

Results: Out of 301 patients clinically diagnosed with VAP, 151 patients were excluded, and the remaining 150 developed 186 episodes of VAP during the study period. The incidence of polymicrobial VAP was 62.9%. Out of 150 patients, 51 patients had monomicrobial VAP, and 99 had polymicrobial VAP. On univariate analysis, diabetes mellitus and poor sensorium (Glasgow Coma Scale [GCS] score <8) during endotracheal intubation; 30-day outcome, mean days of mechanical ventilation after VAP diagnosis and days in ICU; and CAUTI were significantly associated with polymicrobial VAP. On multivariable logistic regression, poor sensorium (GCS score <8) at the time of endotracheal intubation was an independent predictor of polymicrobial VAP.

Conclusion: The incidence of polymicrobial VAP is high in the medical ICU and is associated with increased duration of mechanical ventilation, hospital stay, and incidence of CAUTI. Poor GCS score was the single independent predictor of polymicrobial VAP.

背景:呼吸机相关性肺炎(VAP)是重症监护病房最常见的医院感染,且死亡率高。目的:本研究旨在估计多微生物VAP的频率、结果和预测因素。方法:对2016年7月至2018年7月在印度某三级医院重症监护病房机械通气的成年患者进行前瞻性观察研究,随访30天。将患者分为单微生物组和多微生物组。我们比较了30天的结局参数,如出院、住院、死亡和并发症,如导尿管相关性尿路感染(CAUTI)、中央静脉相关性血流感染(CRBSI)、菌血症和肺塌陷。采用多元logistic回归分析确定多微生物VAP的预测因素。结果:在301例临床诊断为VAP的患者中,151例患者被排除,其余150例患者在研究期间发生了186次VAP发作。多微生物VAP发生率为62.9%。在150例患者中,51例为单微生物VAP, 99例为多微生物VAP。单因素分析,糖尿病和感觉不良(格拉斯哥昏迷量表[GCS])评分结论:内科ICU患者多微生物性VAP发生率较高,与机械通气时间、住院时间和CAUTI发生率增加有关。GCS评分差是多微生物VAP的单一独立预测因子。
{"title":"Poor Sensorium at the Time of Intubation Predicts Polymicrobial Ventilator Associated Pneumonia.","authors":"Ramachandran Natarajan,&nbsp;Venkateswaran Ramanathan,&nbsp;Sujatha Sistla","doi":"10.2147/TCRM.S337341","DOIUrl":"https://doi.org/10.2147/TCRM.S337341","url":null,"abstract":"<p><strong>Background: </strong>Ventilator-associated pneumonia (VAP) is the most common nosocomial infection in the intensive care unit and is associated with a high mortality rate.</p><p><strong>Aim: </strong>The study was conducted to estimate the frequency, outcomes, and predictors of polymicrobial VAP.</p><p><strong>Methods: </strong>A prospective observational study was conducted in mechanically ventilated adult patients in the medical intensive care unit in a tertiary care hospital in India from July 2016 to July 2018 with a 30-day follow-up period. The patients were grouped into monomicrobial and polymicrobial VAP. We compared the 30-day outcome parameters such as discharge from hospital, in-hospital stay, death, and complications such as catheter associated urinary tract infection (CAUTI), central line associated blood stream infection (CRBSI), bacteremia and collapse of lung. The predictors of polymicrobial VAP were identified by multiple logistic regression.</p><p><strong>Results: </strong>Out of 301 patients clinically diagnosed with VAP, 151 patients were excluded, and the remaining 150 developed 186 episodes of VAP during the study period. The incidence of polymicrobial VAP was 62.9%. Out of 150 patients, 51 patients had monomicrobial VAP, and 99 had polymicrobial VAP. On univariate analysis, diabetes mellitus and poor sensorium (Glasgow Coma Scale [GCS] score <8) during endotracheal intubation; 30-day outcome, mean days of mechanical ventilation after VAP diagnosis and days in ICU; and CAUTI were significantly associated with polymicrobial VAP. On multivariable logistic regression, poor sensorium (GCS score <8) at the time of endotracheal intubation was an independent predictor of polymicrobial VAP.</p><p><strong>Conclusion: </strong>The incidence of polymicrobial VAP is high in the medical ICU and is associated with increased duration of mechanical ventilation, hospital stay, and incidence of CAUTI. Poor GCS score was the single independent predictor of polymicrobial VAP.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/88/tcrm-18-125.PMC8860453.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39959179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Multivariable Analysis of Risk Factors Affecting Dislocation After Bipolar Hemiarthroplasty in Patients with Femoral Neck Fracture. 影响股骨颈骨折双极半关节置换术后脱位的多因素分析。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-02-09 eCollection Date: 2022-01-01 DOI: 10.2147/TCRM.S350213
Yuhui Yang, Guangtao Fu, Qingtian Li, Ruiying Zhang, Weihong Liao, Yuanchen Ma, Qiujian Zheng

Objective: This study aimed to investigate the risk factors associated with dislocation and dissociation following bipolar hemiarthroplasty (HA) for the treatment of patients with femoral neck fractures.

Methods: We retrospectively reviewed 462 patients (479 hips) treated with bipolar HA from January 2010 to January 2020. All patients received posterolateral approaches and a minimum follow-up of at least 2 years regularly. A case-control study was performed to analyze the risk factors of dislocation regarding patient demographics, coexisting diseases, surgical and morphologic features. Multivariable logistic regression analysis for independent risk factors affecting dislocation and dissociation was also performed.

Results: The dislocation rate was 5.01%, and the mean time from HA to the first incident of dislocation was 38.75 days. Patient-related factors, including operation side, prosthesis type, and neuromuscular disease, did not differ significantly. Regarding the morphological factors, a significant difference was observed in center-edge (CE) angle, abduction angle, acetabular depth, depth/width ratio, rotation center (RC) to greater trochanter tip (GTT) vertical distance, RC to GTT vertical distance difference, RC to GTT horizontal distance, RC to GTT horizontal distance difference, offset difference, and offset discrepancy. Further, decreased CE angle, increased abduction angle, decreased RC to GTT vertical distance, decreased offset difference and increased offset discrepancy were determined to be independent risk factors of dislocation. The proportion of patients experiencing dissociation was 1.04%. All the implanted femoral heads were smaller than 43 mm, which was determined to be the risk factor of dissociation.

Conclusion: Decreased CE angle, RC to GTT vertical distance, offset difference, and increased abduction angle, offset discrepancy were determined to be independent risk factors of HA dislocation. Once dislocation risk was detected by simulated templating, THA or changing surgical approach should be considered to avoid evitable perioperative complications.

目的:本研究旨在探讨双极半关节置换术(HA)治疗股骨颈骨折患者后脱位和分离的相关危险因素。方法:我们回顾性分析了2010年1月至2020年1月期间接受双相HA治疗的462例患者(479髋)。所有患者均接受后外侧入路手术,定期随访至少2年。通过病例对照研究,分析脱位的危险因素,包括患者人口统计学、共存疾病、手术和形态学特征。对影响脱位和游离的独立危险因素进行多变量logistic回归分析。结果:脱位率为5.01%,HA至首次脱位平均时间为38.75 d。患者相关因素,包括手术侧、假体类型和神经肌肉疾病,无显著差异。在形态学因素方面,中心边缘(CE)角、外展角、髋臼深度、深度/宽度比、旋转中心(RC)与大转子尖端(GTT)垂直距离、旋转中心与大转子尖端(GTT)垂直距离、旋转中心与大转子尖端(GTT)水平距离、旋转中心与大转子尖端(GTT)水平距离、旋转中心与大转子尖端(GTT)水平距离、偏移量差异、偏移量差异存在显著性差异。CE角减小、外展角增大、RC - GTT垂直距离减小、偏移差减小、偏移差增大是脱位的独立危险因素。出现分离的患者比例为1.04%。所有植入的股骨头均小于43 mm,确定这是分离的危险因素。结论:CE角减小、RC与GTT垂直距离减小、偏移差增大、外展角增大、偏移差增大是HA脱位的独立危险因素。一旦通过模拟模板检测到脱位风险,应考虑THA或改变手术入路,以避免不可避免的围手术期并发症。
{"title":"Multivariable Analysis of Risk Factors Affecting Dislocation After Bipolar Hemiarthroplasty in Patients with Femoral Neck Fracture.","authors":"Yuhui Yang,&nbsp;Guangtao Fu,&nbsp;Qingtian Li,&nbsp;Ruiying Zhang,&nbsp;Weihong Liao,&nbsp;Yuanchen Ma,&nbsp;Qiujian Zheng","doi":"10.2147/TCRM.S350213","DOIUrl":"https://doi.org/10.2147/TCRM.S350213","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the risk factors associated with dislocation and dissociation following bipolar hemiarthroplasty (HA) for the treatment of patients with femoral neck fractures.</p><p><strong>Methods: </strong>We retrospectively reviewed 462 patients (479 hips) treated with bipolar HA from January 2010 to January 2020. All patients received posterolateral approaches and a minimum follow-up of at least 2 years regularly. A case-control study was performed to analyze the risk factors of dislocation regarding patient demographics, coexisting diseases, surgical and morphologic features. Multivariable logistic regression analysis for independent risk factors affecting dislocation and dissociation was also performed.</p><p><strong>Results: </strong>The dislocation rate was 5.01%, and the mean time from HA to the first incident of dislocation was 38.75 days. Patient-related factors, including operation side, prosthesis type, and neuromuscular disease, did not differ significantly. Regarding the morphological factors, a significant difference was observed in center-edge (CE) angle, abduction angle, acetabular depth, depth/width ratio, rotation center (RC) to greater trochanter tip (GTT) vertical distance, RC to GTT vertical distance difference, RC to GTT horizontal distance, RC to GTT horizontal distance difference, offset difference, and offset discrepancy. Further, decreased CE angle, increased abduction angle, decreased RC to GTT vertical distance, decreased offset difference and increased offset discrepancy were determined to be independent risk factors of dislocation. The proportion of patients experiencing dissociation was 1.04%. All the implanted femoral heads were smaller than 43 mm, which was determined to be the risk factor of dissociation.</p><p><strong>Conclusion: </strong>Decreased CE angle, RC to GTT vertical distance, offset difference, and increased abduction angle, offset discrepancy were determined to be independent risk factors of HA dislocation. Once dislocation risk was detected by simulated templating, THA or changing surgical approach should be considered to avoid evitable perioperative complications.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/34/tcrm-18-101.PMC8842728.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39638042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Effectiveness of Biofeedback Therapy in Patients with Bowel Dysfunction Following Rectal Cancer Surgery: A Systemic Review with Meta-Analysis. 生物反馈疗法在直肠癌手术后肠功能障碍患者中的有效性:一项系统综述和荟萃分析。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-02-02 eCollection Date: 2022-01-01 DOI: 10.2147/TCRM.S344375
Haoze Li, Ce Guo, Jiale Gao, Hongwei Yao

Objective: To identify, systematically review and synthesize the evidence on the effectiveness of biofeedback therapy in patients with bowel dysfunction following rectal cancer surgery.

Data sources: Four electronic databases (PubMed 1974-2021; Embase1980-2021; Cochrane databases and the trial registers) were systematically searched by reviewers from inception through March 2021.

Study selection: Randomized controlled trials (RCTs), cohort studies, and case series studies were included for adults with bowel dysfunction following rectal cancer surgery. All participants received an intervention of biofeedback treatment. Any outcomes that can evaluate the patient's bowel function were the primary research endpoint, while the quality of life was the second endpoint. The disagreements between the two reviewers were resolved after discussion and the third independent reviewer's ruling. As a result, 12 of 185 studies met selection criteria and were included in the review.

Data extraction: We designed an electronic data extraction form and data were extracted independently. The methodological quality of included studies was assessed using the Cochrane Risk of Bias, the MINORS scale, and the Institute of Health Economics scale.

Data synthesis: Meta-analyses were conducted for case series only and narrative syntheses were completed. Key findings included significant improvements in bowel function as well as health-related quality of life after biofeedback therapy. (Wexner score: t=7, MD=3.33; 95% CI [2.48, 4.18]) and (Vaizey score: t=3, MD=2.46; 95% CI [1.98, 2.93]). Subgroup analysis of Wexner score: receiving electrical stimulation therapy (t=3, MD=2.36; 95% CI [1.51, 3.22]), not receiving electrical stimulation (t=4, MD=3.79;95% CI[2.66, 4.93]); not receiving adjuvant chemoradiotherapy (t=3, MD=2.42;95% CI[1.61, 3.24]), chemotherapy and radiotherapy (t=1, MD=4.10; 95% CI [2.90, 5.30]), radiotherapy and chemotherapy on parts of patients (t=2, MD=3.46;95% CI [1.41, 5.51]), chemotherapy (t=1, MD=4.81; 95% CI [3.38, 6.24]); performing ISR (t=2, MD=3.32;95% CI [0.37, 6.27]), performing AR (t=4, MD=3.08; 95% CI [2.12, 4.04]), performing PLRAS surgery (t=1, MD=4.10;95% CI[2.90, 5.30]).

Conclusion: Although biofeedback therapy may improve intestinal function and quality of life as well as anal function reflected by ARM after surgery, patient satisfaction is still unclear. Due to the scarcity of data, good-quality research is required to delve deeper.

Clinical trial registration number: CRD42020192658.

目的:对生物反馈疗法治疗直肠癌术后肠功能障碍的有效性进行识别、系统回顾和综合。数据来源:四个电子数据库(PubMed 1974-2021;embase1980 - 2021;从研究开始到2021年3月,审稿人系统地检索了Cochrane数据库和试验注册库。研究选择:随机对照试验(RCTs)、队列研究和病例系列研究纳入了直肠癌手术后肠功能障碍的成年人。所有参与者均接受生物反馈治疗干预。任何能够评估患者肠道功能的结果都是主要研究终点,而生活质量是第二终点。两位审稿人之间的分歧在经过讨论和第三位独立审稿人的裁决后得到解决。结果,185项研究中有12项符合选择标准,被纳入本综述。数据提取:设计电子数据提取表,数据独立提取。采用Cochrane偏倚风险量表、未成年人量表和卫生经济学研究所量表评估纳入研究的方法学质量。数据综合:仅对病例系列进行meta分析,并完成叙事综合。主要发现包括生物反馈治疗后肠道功能和健康相关生活质量的显著改善。(Wexner评分:t=7, MD=3.33;95% CI[2.48, 4.18])和(Vaizey评分:t=3, MD=2.46;95% ci[1.98, 2.93])。Wexner评分亚组分析:接受电刺激治疗(t=3, MD=2.36;95% CI[1.51, 3.22]),未接受电刺激(t=4, MD=3.79;95% CI[2.66, 4.93]);未接受辅助放化疗(t=3, MD=2.42;95% CI[1.61, 3.24]),化疗和放疗(t=1, MD=4.10;95% CI[2.90, 5.30])、部分患者放化疗(t=2, MD=3.46;95% CI[1.41, 5.51])、化疗(t=1, MD=4.81;95% ci [3.38, 6.24]);进行ISR (t=2, MD=3.32;95% CI[0.37, 6.27]),进行AR (t=4, MD=3.08;95% CI[2.12, 4.04]),行PLRAS手术(t=1, MD=4.10;95% CI[2.90, 5.30])。结论:虽然生物反馈疗法可以改善术后肠道功能和生活质量以及ARM反映的肛门功能,但患者满意度尚不清楚。由于数据的稀缺性,需要进行高质量的深入研究。临床试验注册号:CRD42020192658。
{"title":"Effectiveness of Biofeedback Therapy in Patients with Bowel Dysfunction Following Rectal Cancer Surgery: A Systemic Review with Meta-Analysis.","authors":"Haoze Li,&nbsp;Ce Guo,&nbsp;Jiale Gao,&nbsp;Hongwei Yao","doi":"10.2147/TCRM.S344375","DOIUrl":"https://doi.org/10.2147/TCRM.S344375","url":null,"abstract":"<p><strong>Objective: </strong>To identify, systematically review and synthesize the evidence on the effectiveness of biofeedback therapy in patients with bowel dysfunction following rectal cancer surgery.</p><p><strong>Data sources: </strong>Four electronic databases (PubMed 1974-2021; Embase1980-2021; Cochrane databases and the trial registers) were systematically searched by reviewers from inception through March 2021.</p><p><strong>Study selection: </strong>Randomized controlled trials (RCTs), cohort studies, and case series studies were included for adults with bowel dysfunction following rectal cancer surgery. All participants received an intervention of biofeedback treatment. Any outcomes that can evaluate the patient's bowel function were the primary research endpoint, while the quality of life was the second endpoint. The disagreements between the two reviewers were resolved after discussion and the third independent reviewer's ruling. As a result, 12 of 185 studies met selection criteria and were included in the review.</p><p><strong>Data extraction: </strong>We designed an electronic data extraction form and data were extracted independently. The methodological quality of included studies was assessed using the Cochrane Risk of Bias, the MINORS scale, and the Institute of Health Economics scale.</p><p><strong>Data synthesis: </strong>Meta-analyses were conducted for case series only and narrative syntheses were completed. Key findings included significant improvements in bowel function as well as health-related quality of life after biofeedback therapy. (Wexner score: t=7, MD=3.33; 95% CI [2.48, 4.18]) and (Vaizey score: t=3, MD=2.46; 95% CI [1.98, 2.93]). Subgroup analysis of Wexner score: receiving electrical stimulation therapy (t=3, MD=2.36; 95% CI [1.51, 3.22]), not receiving electrical stimulation (t=4, MD=3.79;95% CI[2.66, 4.93]); not receiving adjuvant chemoradiotherapy (t=3, MD=2.42;95% CI[1.61, 3.24]), chemotherapy and radiotherapy (t=1, MD=4.10; 95% CI [2.90, 5.30]), radiotherapy and chemotherapy on parts of patients (t=2, MD=3.46;95% CI [1.41, 5.51]), chemotherapy (t=1, MD=4.81; 95% CI [3.38, 6.24]); performing ISR (t=2, MD=3.32;95% CI [0.37, 6.27]), performing AR (t=4, MD=3.08; 95% CI [2.12, 4.04]), performing PLRAS surgery (t=1, MD=4.10;95% CI[2.90, 5.30]).</p><p><strong>Conclusion: </strong>Although biofeedback therapy may improve intestinal function and quality of life as well as anal function reflected by ARM after surgery, patient satisfaction is still unclear. Due to the scarcity of data, good-quality research is required to delve deeper.</p><p><strong>Clinical trial registration number: </strong>CRD42020192658.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bb/e4/tcrm-18-71.PMC8819167.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39904567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Efficacy and Safety Profile of Remimazolam for Sedation in Adults Undergoing Short Surgical Procedures. 雷马唑仑用于成人短期外科手术镇静的有效性和安全性。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-02-02 eCollection Date: 2022-01-01 DOI: 10.2147/TCRM.S304556
Yasuhiro Morimoto

Sedation for short-term procedures is increasingly being used in clinical practice. Selection of appropriate drugs is important for effective and safe sedation; however, an ideal sedative remains unavailable. Remimazolam is a novel, ultrafast-acting benzodiazepine with a shorter duration of action than other agents in this class. It is currently expected to become a popular agent for short-term procedural sedation. Remimazolam shows higher clearance, a smaller volume of distribution, and a shorter half-life than midazolam. It showed dose-dependent sedative action, with onset of sedation within 60s of administration. The results of clinical trials indicate that remimazolam is more useful than midazolam for short procedural sedation such as in patients who undergo colonoscopy and that its safety profile is comparable with that of midazolam. Anesthesia-induced vascular pain is lesser and reduction in blood pressure is lesser with remimazolam than with propofol. Moreover, the availability of flumazenil (a benzodiazepine antagonist) is a specific advantage of remimazolam. These characteristics and the results of clinical trials suggest that remimazolam will be a safer alternative to previous sedative drugs for sedation during the short surgical procedures. Although short-acting agents are useful, they might lead to immediate hyper-sedation. Remimazolam is a promising agent for short-term procedural sedation; however, clinicians should be mindful of the risks of this agent.

在临床实践中越来越多地使用短期手术中的镇静。选择合适的药物是有效和安全镇静的重要因素;然而,目前还没有理想的镇静剂。雷马唑仑是一种新型的超速效苯二氮卓类药物,其作用时间比同类药物中的其他药物短。目前,它有望成为短期程序性镇静的常用药物。雷马唑仑比咪达唑仑清除率高,分布体积小,半衰期短。其镇静作用呈剂量依赖性,在给药后60秒内起效。临床试验结果表明,雷马唑仑比咪达唑仑更适用于短时间的程序性镇静,例如在接受结肠镜检查的患者中,其安全性与咪达唑仑相当。与异丙酚相比,雷马唑仑麻醉引起的血管疼痛更小,血压的降低也更小。此外,氟马西尼(一种苯二氮卓类拮抗剂)的可用性是雷马唑仑的一个特殊优势。这些特点和临床试验结果表明,在短时间外科手术中,雷马唑仑将是一种比以前的镇静药物更安全的镇静选择。虽然短效药物是有用的,但它们可能会导致立即过度镇静。雷马唑仑是一种很有前途的短期程序性镇静药物;然而,临床医生应该注意这种药物的风险。
{"title":"Efficacy and Safety Profile of Remimazolam for Sedation in Adults Undergoing Short Surgical Procedures.","authors":"Yasuhiro Morimoto","doi":"10.2147/TCRM.S304556","DOIUrl":"https://doi.org/10.2147/TCRM.S304556","url":null,"abstract":"<p><p>Sedation for short-term procedures is increasingly being used in clinical practice. Selection of appropriate drugs is important for effective and safe sedation; however, an ideal sedative remains unavailable. Remimazolam is a novel, ultrafast-acting benzodiazepine with a shorter duration of action than other agents in this class. It is currently expected to become a popular agent for short-term procedural sedation. Remimazolam shows higher clearance, a smaller volume of distribution, and a shorter half-life than midazolam. It showed dose-dependent sedative action, with onset of sedation within 60s of administration. The results of clinical trials indicate that remimazolam is more useful than midazolam for short procedural sedation such as in patients who undergo colonoscopy and that its safety profile is comparable with that of midazolam. Anesthesia-induced vascular pain is lesser and reduction in blood pressure is lesser with remimazolam than with propofol. Moreover, the availability of flumazenil (a benzodiazepine antagonist) is a specific advantage of remimazolam. These characteristics and the results of clinical trials suggest that remimazolam will be a safer alternative to previous sedative drugs for sedation during the short surgical procedures. Although short-acting agents are useful, they might lead to immediate hyper-sedation. Remimazolam is a promising agent for short-term procedural sedation; however, clinicians should be mindful of the risks of this agent.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/21/b6/tcrm-18-95.PMC8819169.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39904568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Risk Factors for Asymptomatic and Symptomatic Intracranial Atherosclerosis Determined by Magnetic Resonance Vessel Wall Imaging in Chinese Population: A Case-Control Study. 磁共振血管壁成像测定无症状和症状性颅内动脉粥样硬化的危险因素:一项病例对照研究。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-01-12 eCollection Date: 2022-01-01 DOI: 10.2147/TCRM.S335401
Yongjun Han, Runhua Zhang, Dandan Yang, Dongye Li, Hualu Han, Huiyu Qiao, Shuo Chen, Yu Wang, Miaoxin Yu, Yin Hong, Zhiqun Wang, Xihai Zhao, Gaifen Liu

Background and purpose: The association between risk factors and intracranial atherosclerosis disease (ICAD) determined by magnetic resonance (MR) vessel wall imaging in Chinese population has not been investigated. The aim of this study was to investigate the associations of conventional vascular risk factors with asymptomatic and symptomatic ICAD using MR vessel wall imaging in Chinese population.

Methods: The study population was recruited from two cohort studies of ICASMAP and CAMERA comprised 104 symptomatic ICAD subjects (57.1 ± 11.1 years; 35.6% females), 51 asymptomatic ICAD subjects (70.1 ± 8.4 years; 50.0% females) and 418 controls (58.0 ± 13.3 years; 61.0% females) defined as asymptomatic subjects without ICAD on MR vessel wall imaging. We compared the vascular risk factors between the three groups using a multivariate logistic regression analysis.

Results: Compared with controls, there was a significant positive association between age (OR: 1.07, 95% CI: 1.03-1.10, p < 0.001) and hypertension (OR: 3.03, 95% CI: 1.45-6.36, p = 0.003) and asymptomatic ICAD. There was a positive association of smoking (OR: 3.41, 95% CI: 1.57-7.42, p = 0.001), hypertension (OR: 7.43, 95% CI: 3.81-14.49, p < 0.001) and diabetes (OR: 3.54, 95% CI: 1.93-6.49, p < 0.001) and an inverse association of high-density lipoprotein (HDL) (p < 0.017) with symptomatic ICAD. Compared to asymptomatic ICAD, there was a significant inverse association of age (OR: 0.86, 95% CI: 0.81-0.92, p < 0.001) and HDL (p < 0.001) with symptomatic ICAD.

Conclusion: Old age and hypertension are associated with asymptomatic ICAD and smoking, hypertension, diabetes and lower HDL are associated with an increased risk of symptomatic ICAD in Chinese population.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT03417063.

背景与目的:中国人群中磁共振(MR)血管壁成像确定的危险因素与颅内动脉粥样硬化疾病(ICAD)之间的关系尚未研究。本研究的目的是利用MR血管壁成像技术探讨中国人群中常规血管危险因素与无症状和有症状ICAD的关系。方法:研究人群从ICASMAP和CAMERA两项队列研究中招募,包括104名有症状的ICAD受试者(57.1±11.1岁;无症状ICAD患者51例(70.1±8.4岁;50.0%女性),对照组418例(58.0±13.3岁;61.0%女性)定义为MR血管壁成像无ICAD的无症状受试者。我们使用多变量logistic回归分析比较了三组之间的血管危险因素。结果:与对照组相比,年龄(OR: 1.07, 95% CI: 1.03-1.10, p < 0.001)和高血压(OR: 3.03, 95% CI: 1.45-6.36, p = 0.003)与无症状ICAD存在显著正相关。吸烟(OR: 3.41, 95% CI: 1.57-7.42, p = 0.001)、高血压(OR: 7.43, 95% CI: 3.81-14.49, p < 0.001)和糖尿病(OR: 3.54, 95% CI: 1.93-6.49, p < 0.001)与症状性ICAD呈正相关,高密度脂蛋白(HDL)呈负相关(p < 0.017)。与无症状ICAD相比,年龄(OR: 0.86, 95% CI: 0.81-0.92, p < 0.001)和HDL (p < 0.001)与有症状ICAD呈显著负相关。结论:老年和高血压与无症状ICAD相关,吸烟、高血压、糖尿病和低HDL与中国人群出现症状性ICAD的风险增加相关。临床试验注册:网址:http://www.clinicaltrials.gov。唯一标识符:NCT03417063。
{"title":"Risk Factors for Asymptomatic and Symptomatic Intracranial Atherosclerosis Determined by Magnetic Resonance Vessel Wall Imaging in Chinese Population: A Case-Control Study.","authors":"Yongjun Han,&nbsp;Runhua Zhang,&nbsp;Dandan Yang,&nbsp;Dongye Li,&nbsp;Hualu Han,&nbsp;Huiyu Qiao,&nbsp;Shuo Chen,&nbsp;Yu Wang,&nbsp;Miaoxin Yu,&nbsp;Yin Hong,&nbsp;Zhiqun Wang,&nbsp;Xihai Zhao,&nbsp;Gaifen Liu","doi":"10.2147/TCRM.S335401","DOIUrl":"https://doi.org/10.2147/TCRM.S335401","url":null,"abstract":"<p><strong>Background and purpose: </strong>The association between risk factors and intracranial atherosclerosis disease (ICAD) determined by magnetic resonance (MR) vessel wall imaging in Chinese population has not been investigated. The aim of this study was to investigate the associations of conventional vascular risk factors with asymptomatic and symptomatic ICAD using MR vessel wall imaging in Chinese population.</p><p><strong>Methods: </strong>The study population was recruited from two cohort studies of ICASMAP and CAMERA comprised 104 symptomatic ICAD subjects (57.1 ± 11.1 years; 35.6% females), 51 asymptomatic ICAD subjects (70.1 ± 8.4 years; 50.0% females) and 418 controls (58.0 ± 13.3 years; 61.0% females) defined as asymptomatic subjects without ICAD on MR vessel wall imaging. We compared the vascular risk factors between the three groups using a multivariate logistic regression analysis.</p><p><strong>Results: </strong>Compared with controls, there was a significant positive association between age (OR: 1.07, 95% CI: 1.03-1.10, p < 0.001) and hypertension (OR: 3.03, 95% CI: 1.45-6.36, p = 0.003) and asymptomatic ICAD. There was a positive association of smoking (OR: 3.41, 95% CI: 1.57-7.42, p = 0.001), hypertension (OR: 7.43, 95% CI: 3.81-14.49, p < 0.001) and diabetes (OR: 3.54, 95% CI: 1.93-6.49, p < 0.001) and an inverse association of high-density lipoprotein (HDL) (p < 0.017) with symptomatic ICAD. Compared to asymptomatic ICAD, there was a significant inverse association of age (OR: 0.86, 95% CI: 0.81-0.92, p < 0.001) and HDL (p < 0.001) with symptomatic ICAD.</p><p><strong>Conclusion: </strong>Old age and hypertension are associated with asymptomatic ICAD and smoking, hypertension, diabetes and lower HDL are associated with an increased risk of symptomatic ICAD in Chinese population.</p><p><strong>Clinical trial registration: </strong>URL: http://www.clinicaltrials.gov. Unique identifier: NCT03417063.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/91/tcrm-18-61.PMC8764293.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39957437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Pediatric Adrenal Insufficiency: Challenges and Solutions. 儿童肾上腺功能不全:挑战和解决方案。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-01-11 eCollection Date: 2022-01-01 DOI: 10.2147/TCRM.S294065
Daniela Nisticò, Benedetta Bossini, Simone Benvenuto, Maria Chiara Pellegrin, Gianluca Tornese

Adrenal insufficiency is an insidious diagnosis that can be initially misdiagnosed as other life-threatening endocrine conditions, as well as sepsis, metabolic disorders, or cardiovascular disease. In newborns, cortisol deficiency causes delayed bile acid synthesis and transport maturation, determining prolonged cholestatic jaundice. Subclinical adrenal insufficiency is a particular challenge for a pediatric endocrinologist, representing the preclinical stage of acute adrenal insufficiency. Although often included in the extensive work-up of an unwell child, a single cortisol value is usually difficult to interpret; therefore, in most cases, a dynamic test is required for diagnosis to assess the hypothalamic-pituitary-adrenal axis. Stimulation tests using corticotropin analogs are recommended as first-line for diagnosis. All patients with adrenal insufficiency need long-term glucocorticoid replacement therapy, and oral hydrocortisone is the first-choice replacement treatment in pediatric. However, children that experience low cortisol concentrations and symptoms of cortisol insufficiency can take advantage using a modified release hydrocortisone formulation. The acute adrenal crisis is a life-threatening condition in all ages, treatment is effective if administered promptly, and it must not be delayed for any reason.

肾上腺功能不全是一种潜在的诊断,最初可能被误诊为其他危及生命的内分泌疾病,以及败血症、代谢紊乱或心血管疾病。在新生儿,皮质醇缺乏导致延迟胆汁酸合成和转运成熟,决定延长胆汁淤积性黄疸。亚临床肾上腺功能不全对儿科内分泌学家来说是一个特别的挑战,代表急性肾上腺功能不全的临床前阶段。虽然经常包括在一个不健康的孩子的广泛的工作中,一个单一的皮质醇值通常很难解释;因此,在大多数情况下,诊断需要动态测试来评估下丘脑-垂体-肾上腺轴。建议使用促肾上腺皮质激素类似物进行刺激试验作为诊断的一线方法。肾上腺功能不全患者均需要长期糖皮质激素替代治疗,口服氢化可的松是儿科替代治疗的首选。然而,经历低皮质醇浓度和皮质醇不足症状的儿童可以利用改良释放氢化可的松制剂。急性肾上腺危机在所有年龄段都是一种危及生命的疾病,如果及时给予治疗是有效的,并且不得以任何理由拖延治疗。
{"title":"Pediatric Adrenal Insufficiency: Challenges and Solutions.","authors":"Daniela Nisticò,&nbsp;Benedetta Bossini,&nbsp;Simone Benvenuto,&nbsp;Maria Chiara Pellegrin,&nbsp;Gianluca Tornese","doi":"10.2147/TCRM.S294065","DOIUrl":"https://doi.org/10.2147/TCRM.S294065","url":null,"abstract":"<p><p>Adrenal insufficiency is an insidious diagnosis that can be initially misdiagnosed as other life-threatening endocrine conditions, as well as sepsis, metabolic disorders, or cardiovascular disease. In newborns, cortisol deficiency causes delayed bile acid synthesis and transport maturation, determining prolonged cholestatic jaundice. Subclinical adrenal insufficiency is a particular challenge for a pediatric endocrinologist, representing the preclinical stage of acute adrenal insufficiency. Although often included in the extensive work-up of an unwell child, a single cortisol value is usually difficult to interpret; therefore, in most cases, a dynamic test is required for diagnosis to assess the hypothalamic-pituitary-adrenal axis. Stimulation tests using corticotropin analogs are recommended as first-line for diagnosis. All patients with adrenal insufficiency need long-term glucocorticoid replacement therapy, and oral hydrocortisone is the first-choice replacement treatment in pediatric. However, children that experience low cortisol concentrations and symptoms of cortisol insufficiency can take advantage using a modified release hydrocortisone formulation. The acute adrenal crisis is a life-threatening condition in all ages, treatment is effective if administered promptly, and it must not be delayed for any reason.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/dd/tcrm-18-47.PMC8761033.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39834852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Prognostic Implications of the Admission Cardiac Troponin I Levels and Door-to-Balloon Time on Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. 经皮冠状动脉介入治疗st段抬高型心肌梗死患者入院时心肌肌钙蛋白I水平和从门到球囊时间对临床结果的影响
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-01-07 eCollection Date: 2022-01-01 DOI: 10.2147/TCRM.S335045
Longguo Zhao, Minglong Xin, Xianji Piao, Shengming Zhang, Yanglong Li, Xian Wu Cheng

Background: The prognostic implications of the admission cTnI level and D2B time combined on in-hospital and 1-year heart failure (HF) and mortality in STEMI patients undergoing a primary percutaneous coronary intervention (PCI) are remain uncertain.

Methods and results: We divided the consecutive 1485 STEMI patients who underwent PCI from January 2015 to October 2019 at our hospital into three groups based on their admission cTnI levels: normal group (<0.1 ng/mL), middle group (0.1 to less than 3 ng/mL), and high group (≥3 ng/mL) and into two groups by their D2B times: >90 min (>90-D2B) and ≤90 min (≤90-D2B). During the in-hospital and 1-year follow-up periods, the incidence of composite clinical events increased significantly with the increase in the admission cTnI level (p < 0.05). In-hospital, the composite rate of death and HF events was significantly higher in the >90-D2B group compared to the ≤90-D2B group (p = 0.006), but its influence disappeared in the 1-year follow-up (p > 0.05). A multivariable logistic analysis revealed that, in the ≤90-D2B group, with the exception of the cTnI ≥3 ng/mL patients, the cTnI level had no effect on in-hospital or 1-year outcomes; in >90-D2B group, cTnI ≥3ng/mL increased outcomes in both periods.

Conclusion: High cTnI levels (≥3 ng/mL) on admission are independent of the D2B time for predicting in-hospital and 1-year cardiac events in STEMI patients undergoing PCI.

背景:入院时cTnI水平和D2B时间对接受初级经皮冠状动脉介入治疗(PCI)的STEMI患者住院和1年心力衰竭(HF)及死亡率的预后影响尚不确定。方法与结果:我们将2015年1月至2019年10月在我院连续行PCI治疗的1485例STEMI患者根据入院时cTnI水平分为正常组(90 min (>90- d2b)和≤90 min(≤90- d2b)三组。住院及1年随访期间,复合临床事件发生率随入院cTnI水平的升高而显著增高(p < 0.05)。院内>90-D2B组的死亡率和HF事件复合发生率显著高于≤90-D2B组(p = 0.006),但1年随访后其影响消失(p > 0.05)。多变量logistic分析显示,在≤90-D2B组中,除了cTnI≥3 ng/mL的患者外,cTnI水平对住院或1年预后没有影响;>90-D2B组,cTnI≥3ng/mL均可提高两期预后。结论:入院时高cTnI水平(≥3ng /mL)与D2B时间无关,可用于预测行PCI的STEMI患者住院和1年心脏事件。
{"title":"Prognostic Implications of the Admission Cardiac Troponin I Levels and Door-to-Balloon Time on Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.","authors":"Longguo Zhao,&nbsp;Minglong Xin,&nbsp;Xianji Piao,&nbsp;Shengming Zhang,&nbsp;Yanglong Li,&nbsp;Xian Wu Cheng","doi":"10.2147/TCRM.S335045","DOIUrl":"https://doi.org/10.2147/TCRM.S335045","url":null,"abstract":"<p><strong>Background: </strong>The prognostic implications of the admission cTnI level and D2B time combined on in-hospital and 1-year heart failure (HF) and mortality in STEMI patients undergoing a primary percutaneous coronary intervention (PCI) are remain uncertain.</p><p><strong>Methods and results: </strong>We divided the consecutive 1485 STEMI patients who underwent PCI from January 2015 to October 2019 at our hospital into three groups based on their admission cTnI levels: normal group (<0.1 ng/mL), middle group (0.1 to less than 3 ng/mL), and high group (≥3 ng/mL) and into two groups by their D2B times: >90 min (>90-D2B) and ≤90 min (≤90-D2B). During the in-hospital and 1-year follow-up periods, the incidence of composite clinical events increased significantly with the increase in the admission cTnI level (p < 0.05). In-hospital, the composite rate of death and HF events was significantly higher in the >90-D2B group compared to the ≤90-D2B group (p = 0.006), but its influence disappeared in the 1-year follow-up (p > 0.05). A multivariable logistic analysis revealed that, in the ≤90-D2B group, with the exception of the cTnI ≥3 ng/mL patients, the cTnI level had no effect on in-hospital or 1-year outcomes; in >90-D2B group, cTnI ≥3ng/mL increased outcomes in both periods.</p><p><strong>Conclusion: </strong>High cTnI levels (≥3 ng/mL) on admission are independent of the D2B time for predicting in-hospital and 1-year cardiac events in STEMI patients undergoing PCI.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/15/tcrm-18-31.PMC8752064.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39819192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional and Physical Prehabilitation in Elective Orthopedic Surgery: Rationale and Proposal for Implementation. 选择性骨科手术中的营养和身体康复:基本原理和实施建议。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-01-06 eCollection Date: 2022-01-01 DOI: 10.2147/TCRM.S341953
Matteo Briguglio, Thomas W Wainwright

In the past, good food and exercise were not considered effective interventions to promote recovery in orthopedic surgery, and prolonged bed rest with not many calories has been deemed sufficient for the proper health restoration until the end of the nineteenth century. The advancement of scientific knowledge proved just the opposite, thus pushing health professionals to sustain the nutritional status and physical fitness of surgical patients. Nevertheless, the impoverishment of lifestyles and the lengthening of life expectancy have invariably contrasted the strength of constitution, giving rise to two of the most hazardous conditions for orthopedic patients: malnutrition and sarcopenia, often hiding nutrient deficits and poor body composition. These conditions are known to be negative prognostic factors in several areas of major surgery, including hip replacement, knee replacement, and spine surgery. Scoring systems to screen for malnutrition and physical inabilities exist, but disciplined management of the derived risks remains untested, potentially hindering the implementation of research findings into practice. A methodical approach of preoperative analysis, critical monitoring, and risk correction before surgery could lead to a substantial improvement of the prognosis while warranting the safety of patients and the efficiency of enhanced recovery after surgery pathways. The aim of this article is to discuss from a dietetic and exercise perspective the ideal nutritional and physical prehabilitation to lay the foundations for designing the appropriate integration of dietitians and physiotherapists in a preoperative enhanced recovery pathway. This methodical analysis could effectively calculate the patient's risks, detect the best choices for resolving the risk, underline the ignored aspects of perioperative care, and represent a concrete means to integrate novel discoveries.

在过去,良好的食物和运动并不被认为是促进骨科手术恢复的有效干预措施,直到19世纪末,长时间的卧床休息和不摄入太多卡路里才被认为足以恢复健康。科学知识的进步恰恰证明了这一点,从而促使卫生专业人员维持手术患者的营养状况和身体健康。然而,生活方式的贫乏和预期寿命的延长总是与体质的强健形成对比,给骨科病人带来了两种最危险的状况:营养不良和肌肉减少症,往往隐藏着营养缺乏和身体成分不佳。这些情况在包括髋关节置换术、膝关节置换术和脊柱手术在内的一些大手术中被认为是负面的预后因素。目前存在筛选营养不良和身体残疾的评分系统,但对衍生风险的严格管理仍未经检验,这可能会阻碍将研究结果付诸实践。系统的术前分析、危重监测和术前风险纠正可以显著改善预后,同时保证患者的安全性和术后恢复的效率。本文旨在从饮食和运动的角度探讨理想的营养和身体康复,为在术前增强康复途径中设计适当的营养师和物理治疗师整合奠定基础。这种方法分析可以有效地计算患者的风险,发现解决风险的最佳选择,强调围手术期护理被忽视的方面,并代表了整合新发现的具体手段。
{"title":"Nutritional and Physical Prehabilitation in Elective Orthopedic Surgery: Rationale and Proposal for Implementation.","authors":"Matteo Briguglio,&nbsp;Thomas W Wainwright","doi":"10.2147/TCRM.S341953","DOIUrl":"https://doi.org/10.2147/TCRM.S341953","url":null,"abstract":"<p><p>In the past, good food and exercise were not considered effective interventions to promote recovery in orthopedic surgery, and prolonged bed rest with not many calories has been deemed sufficient for the proper health restoration until the end of the nineteenth century. The advancement of scientific knowledge proved just the opposite, thus pushing health professionals to sustain the nutritional status and physical fitness of surgical patients. Nevertheless, the impoverishment of lifestyles and the lengthening of life expectancy have invariably contrasted the strength of constitution, giving rise to two of the most hazardous conditions for orthopedic patients: malnutrition and sarcopenia, often hiding nutrient deficits and poor body composition. These conditions are known to be negative prognostic factors in several areas of major surgery, including hip replacement, knee replacement, and spine surgery. Scoring systems to screen for malnutrition and physical inabilities exist, but disciplined management of the derived risks remains untested, potentially hindering the implementation of research findings into practice. A methodical approach of preoperative analysis, critical monitoring, and risk correction before surgery could lead to a substantial improvement of the prognosis while warranting the safety of patients and the efficiency of enhanced recovery after surgery pathways. The aim of this article is to discuss from a dietetic and exercise perspective the ideal nutritional and physical prehabilitation to lay the foundations for designing the appropriate integration of dietitians and physiotherapists in a preoperative enhanced recovery pathway. This methodical analysis could effectively calculate the patient's risks, detect the best choices for resolving the risk, underline the ignored aspects of perioperative care, and represent a concrete means to integrate novel discoveries.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/db/tcrm-18-21.PMC8747789.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39816306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
期刊
Therapeutics and Clinical Risk Management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1